Axsome Therapeutics, Inc. (NASDAQ:AXSM) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) have earned a consensus recommendation of “Moderate Buy” from the twenty-one research firms that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, eighteen have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $251.2632.

Several brokerages have issued reports on AXSM. Cantor Fitzgerald reiterated an “overweight” rating and set a $272.00 target price on shares of Axsome Therapeutics in a research report on Monday, May 4th. Robert W. Baird lifted their target price on shares of Axsome Therapeutics from $241.00 to $246.00 and gave the company an “outperform” rating in a research report on Tuesday, May 5th. Wolfe Research began coverage on shares of Axsome Therapeutics in a research report on Monday, February 23rd. They set an “outperform” rating and a $230.00 target price for the company. HC Wainwright reiterated a “buy” rating on shares of Axsome Therapeutics in a research report on Thursday. Finally, Guggenheim lifted their target price on shares of Axsome Therapeutics from $245.00 to $260.00 and gave the company a “buy” rating in a research report on Monday, May 4th.

Insider Transactions at Axsome Therapeutics

In other news, Director Mark Coleman sold 5,537 shares of the business’s stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $223.39, for a total value of $1,236,910.43. Following the completion of the sale, the director directly owned 29,603 shares in the company, valued at approximately $6,613,014.17. The trade was a 15.76% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, COO Mark L. Jacobson sold 233 shares of the business’s stock in a transaction that occurred on Tuesday, May 5th. The stock was sold at an average price of $228.18, for a total transaction of $53,165.94. Following the completion of the sale, the chief operating officer owned 4,517 shares of the company’s stock, valued at approximately $1,030,689.06. The trade was a 4.91% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 29,787 shares of company stock worth $6,470,391. 20.60% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Axsome Therapeutics

Hedge funds have recently made changes to their positions in the business. Kemnay Advisory Services Inc. bought a new stake in shares of Axsome Therapeutics in the 4th quarter worth approximately $31,000. Hollencrest Capital Management lifted its holdings in shares of Axsome Therapeutics by 400.0% in the 1st quarter. Hollencrest Capital Management now owns 200 shares of the company’s stock worth $34,000 after acquiring an additional 160 shares during the last quarter. Optiver Holding B.V. lifted its holdings in shares of Axsome Therapeutics by 82.3% in the 3rd quarter. Optiver Holding B.V. now owns 288 shares of the company’s stock worth $35,000 after acquiring an additional 130 shares during the last quarter. Ameriflex Group Inc. bought a new stake in shares of Axsome Therapeutics in the 4th quarter worth approximately $37,000. Finally, Essex Investment Management Co. LLC bought a new stake in shares of Axsome Therapeutics in the 3rd quarter worth approximately $38,000. 81.49% of the stock is currently owned by institutional investors.

Axsome Therapeutics Trading Up 0.4%

Shares of Axsome Therapeutics stock opened at $232.32 on Friday. Axsome Therapeutics has a 1 year low of $96.09 and a 1 year high of $242.41. The firm has a market cap of $11.96 billion, a PE ratio of -62.28 and a beta of 0.61. The company has a debt-to-equity ratio of 2.27, a current ratio of 1.39 and a quick ratio of 1.32. The company has a 50 day simple moving average of $202.66 and a two-hundred day simple moving average of $178.42.

Axsome Therapeutics (NASDAQ:AXSM) last announced its earnings results on Monday, May 4th. The company reported ($1.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.41). Axsome Therapeutics had a negative net margin of 26.59% and a negative return on equity of 267.16%. The company had revenue of $191.20 million for the quarter, compared to the consensus estimate of $191.10 million. The company’s revenue was up 57.4% compared to the same quarter last year. Analysts expect that Axsome Therapeutics will post -2.24 earnings per share for the current fiscal year.

About Axsome Therapeutics

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.